Krystal Biotech, Inc. KRYS Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s financing cash flow?
- Krystal Biotech, Inc. (KRYS) reported financing cash flow of -$10.46M in Q1 2026.
- How has Krystal Biotech, Inc.'s financing cash flow changed year-over-year?
- Krystal Biotech, Inc.'s financing cash flow increased by 16.1% year-over-year, from -$12.47M to -$10.46M.
- What is the long-term trend for Krystal Biotech, Inc.'s financing cash flow?
- Over 3 years (2021 to 2024), Krystal Biotech, Inc.'s financing cash flow has grown at a -57.3% compound annual growth rate (CAGR), from $347.88M to $27.01M.
- What does financing cash flow mean?
- The net cash change resulting from equity and debt transactions.
- How do you interpret financing cash flow?
- Positive values often indicate capital raising, while negative values suggest debt repayment or share buybacks.
- How does financing cash flow compare across companies?
- Reflects the company's reliance on external financing versus operational cash flow compared to industry peers.